Stellar Biotechnologies Form 6-K







UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

            

FORM 6-K


REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 AND 15d-16 UNDER

THE  SECURITIES EXCHANGE ACT OF 1934


For the Month of   August 2012            


File No.   000-54598


Stellar Biotechnologies Inc.

(Name of Registrant)


332 E. Scott Street, Port Hueneme, CA 93041

 (Address of principal executive offices)


Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

FORM 20-F __X__

FORM 40-F  ______


Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ___



Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ___


SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Form 6-K to be signed on its behalf by the undersigned, thereunto duly authorized.


Stellar Biotechnologies Inc.

(Registrant)



Dated: August 14, 2012

By:  /s/  "Darrll Brookstein"

Darrell Brookstein

Director


Exhibits:


99.1

News Release dated August 9, 2012

99.2

News Release dated August 9, 2012 (2)






Stellar News Release



STELLAR BIOTECHNOLOGIES ANNOUNCES CHOW AND BRISSON TO NEW C-LEVEL POSTS


PORT HUENEME, CA, (August 9, 2012) -- Stellar Biotechnologies, Inc. ("Stellar") (TSX-V: KLH) (PINKSHEETS: SBOTF) (Frankfurt: RBT) is very pleased to announce that Herbert S. Chow, Ph.D. has been appointed to the position of Chief Technology Officer (CTO) and Catherine Brisson, Ph.D. has been appointed the position of Chief Pharmaceutical Officer (CPO) for the Company.


Stellar’s President & CEO, Frank Oakes said, “This is an important move for Stellar as it fills two key positions on senior management team with two extremely talented professionals with extensive experience in the science and technology surrounding KLH, and a deep understanding of our strategic pathway and product pipeline. I do not believe the Company could have found two more qualified candidates to meet the challenges of these two key positions and support the effective execution of the company’s plan over the next few years.”


New CPO, Catherine Brisson said, “I am very excited to be a part of this technology which perfectly fits the needs of the pharmaceutical industry. I feel confident that my commercial development expertise and strategic insight will contribute to Stellar’s immediate and future successes. I am pleased to be working in this new capacity with the first-class team of scientific, engineering, and business leaders that Stellar has assembled - all focused on tackling a challenging but critically important mission of advancing the innovative KLH therapeutic platform.”


New CTO, Herbert Chow said, “I am looking forward to working with the management team, our Board and Scientific Advisory Board to design and advance an innovative pipeline of KLH based vaccine candidates for the diagnosis and treatment of serious indications with a huge unmet medical need. I am excited to face the challenges ahead and to lead the development of the next generation of infectious disease and oncology vaccine solutions.”


About Stellar Biotechnologies, Inc. (www.StellarBiotech.com)


Stellar Biotechnologies, Inc. (TSX-V: KLH) (U.S. OTC: SBOTF) (Frankfort: RBT) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Potent, yet proven safe in humans, KLH operates as both a vital component for conjugate vaccines (targeting cancer, autoimmune, and infectious diseases) as well as an antigen for measuring immune status. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP­grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom of http://stellarbiotechnologies.com/investors/news releases/


Contact:


Frank Oakes, President & CEO

foakes@stellarbiotech.com

Main +1 (805) 488-2800



There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Stellar News Release




PRESS RELEASE
STOCK OPTIONS GRANTED


PORT HUENEME, CA, (August 9, 2012) -- Stellar Biotechnologies, Inc. (“Stellar”) (TSX-V: KLH) (PINKSHEETS: SBOTF) (Frankfurt: RBT) announces the grant of incentive stock options to officers to purchase an aggregate of 150,000 common shares, exercisable at a price of $0.37 per share for a period of seven years. The options are granted pursuant to Stellar’s Share Option Plan and the vesting provisions contained therein.


About Stellar Biotechnologies, Inc.


Stellar Biotechnologies, Inc. (TSX VENTURE: KLH) (PINKSHEETS: SBOTF) (FRANKFURT: RBT) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Potent, yet proven safe in humans, KLH operates as both a vital component for conjugate vaccines (targeting cancer, autoimmune, and infectious diseases) as well as an antigen for measuring immune status. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom of http://stellarbiotechnologies.com/investors/news_releases/


Contact:

Darrell Brookstein

Executive VP, Corporate Development & Finance

dbrookstein@stellarbiotech.com



There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.